Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ABDUL RAFEH NAQASH

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1528499712
CMS profile
4217943
Location
OKLAHOMA CITY, OK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$222.96

15 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $195.98 13
Education $26.98 2

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ABDUL RAFEH NAQASH

NPI 1528499712 · CMS profile ID 4217943

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

OKLAHOMA CITY, OK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1528499712?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ABDUL RAFEH NAQASH, NPI 1528499712, CMS profile ID 4217943. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1528499712?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). ABDUL RAFEH NAQASH, NPI 1528499712, CMS profile ID 4217943. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1528499712?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
ABDUL RAFEH NAQASH, NPI 1528499712, CMS profile ID 4217943, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1528499712?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

15 matching records · $222.96 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 15 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–15 of 15.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $11.5611/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673817241 CMS
PFIZER INC. $11.9605/28/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673114679 CMS
PFIZER INC. $14.9605/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673230031 CMS
Merck Sharp & Dohme Corporation $15.1405/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695450467 CMS
Merck Sharp & Dohme Corporation $16.1704/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695425145 CMS
AMAG Pharmaceuticals, Inc. $15.0204/08/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698531315 CMS
Celgene Corporation $21.2604/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673413903 CMS
Celgene Corporation $21.2603/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673413991 CMS
Merck Sharp & Dohme Corporation $16.8703/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695352247 CMS
BTG International, Inc. $14.8102/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694920725 CMS
GENZYME CORPORATION $12.7302/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693916391 CMS
Lilly USA, LLC $13.3801/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657645253 CMS
Pharmacyclics LLC, An AbbVie Company $10.9301/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665850287 CMS
Takeda Pharmaceuticals U.S.A., Inc. $11.3801/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697382309 CMS
PFIZER INC. $15.5301/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673054189 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $222.96 15
PY2020 $13.46 1
PY2023 $7,378.87 2
PY2024 $11,838.80 9
PY2025 $3,667.10 15

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $443.22 1
PY2025 Principal investigator $340,851.02 231
PY2024 Principal investigator $416,792.13 124
PY2023 Principal investigator $259,878.25 67
PY2022 Principal investigator $92,521.38 35

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

67 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ADC Therapeutics America, Inc. $895.00 11/22/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-901-101 No dispute reported 06/30/2026 1051209529
Principal investigator 1 ADC Therapeutics America, Inc. $570.00 11/22/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-901-101 No dispute reported 06/30/2026 1051209531
Principal investigator 1 ADC Therapeutics America, Inc. $1,860.00 11/22/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-901-101 No dispute reported 06/30/2026 1051209533
Principal investigator 1 ADC Therapeutics America, Inc. $380.00 11/22/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-901-101 No dispute reported 06/30/2026 1051209535
Principal investigator 1 ADC Therapeutics America, Inc. $150.00 11/22/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-901-101 No dispute reported 06/30/2026 1051209537
Principal investigator 1 ADC Therapeutics America, Inc. $2,500.00 11/22/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-901-101 No dispute reported 06/30/2026 1051209541
Principal investigator 1 ADC Therapeutics America, Inc. $2,500.00 11/22/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-901-101 No dispute reported 06/30/2026 1051209543
Principal investigator 1 Exelixis Inc. $655.00 11/22/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041942071
Principal investigator 1 Exelixis Inc. $4,950.00 11/22/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041942127
Principal investigator 1 Merck Sharp & Dohme LLC $134,900.00 11/14/2023 Non-covered Recipient Entity
University Of Oklahoma OU Health Stephenson Cancer Center
A Phase 1,1b Dose Escalation,Expansion Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1042567143
Principal investigator 1 Exelixis Inc. $3,703.67 11/08/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041942079
Principal investigator 1 Exelixis Inc. $890.00 11/03/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041942119
Principal investigator 1 ADC Therapeutics America, Inc. $2,500.00 10/27/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209551
Principal investigator 1 Eli Lilly and Company $5,000.00 10/18/2023 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
AN OPEN-LABEL MULTICENTER STUDY OF LOXO-435 (LY3866288) IN ADVANCED SOLID TUMOR MALIGNANCIES WITH FGFR3 ALTERATIONS No dispute reported 06/30/2026 1038131809
Principal investigator 1 ADC Therapeutics America, Inc. $150.00 09/29/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209423
Principal investigator 1 ADC Therapeutics America, Inc. $380.00 09/29/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209425
Principal investigator 1 ADC Therapeutics America, Inc. $1,000.00 09/29/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209433
Principal investigator 1 ADC Therapeutics America, Inc. $1,860.00 09/29/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209435
Principal investigator 1 ADC Therapeutics America, Inc. $2,300.63 09/29/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209441
Principal investigator 1 ADC Therapeutics America, Inc. $2,500.00 09/29/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209445
Principal investigator 1 ADC Therapeutics America, Inc. $2,500.00 09/29/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-901-101 No dispute reported 06/30/2026 1051209465
Principal investigator 1 ADC Therapeutics America, Inc. $2,500.00 09/29/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-901-101 No dispute reported 06/30/2026 1051209467
Principal investigator 1 ADC Therapeutics America, Inc. $75.00 09/01/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209413
Principal investigator 1 ADC Therapeutics America, Inc. $93.75 09/01/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209415
Principal investigator 1 ADC Therapeutics America, Inc. $94.00 09/01/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209417
Principal investigator 1 ADC Therapeutics America, Inc. $96.00 09/01/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209419
Principal investigator 1 ADC Therapeutics America, Inc. $135.00 09/01/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209421
Principal investigator 1 ADC Therapeutics America, Inc. $450.00 09/01/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209427
Principal investigator 1 ADC Therapeutics America, Inc. $455.00 09/01/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209429
Principal investigator 1 ADC Therapeutics America, Inc. $500.00 09/01/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209431
Principal investigator 1 ADC Therapeutics America, Inc. $2,047.50 09/01/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209437
Principal investigator 1 ADC Therapeutics America, Inc. $2,300.63 09/01/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209439
Principal investigator 1 ADC Therapeutics America, Inc. $2,500.00 09/01/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209443
Principal investigator 1 ADC Therapeutics America, Inc. $2,500.00 09/01/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209455
Principal investigator 1 ADC Therapeutics America, Inc. $2,500.00 09/01/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209457
Principal investigator 1 ADC Therapeutics America, Inc. $75.00 09/01/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209471
Principal investigator 1 ADC Therapeutics America, Inc. $94.00 09/01/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209473
Principal investigator 1 ADC Therapeutics America, Inc. $135.00 09/01/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209475
Principal investigator 1 ADC Therapeutics America, Inc. $450.00 09/01/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209477
Principal investigator 1 ADC Therapeutics America, Inc. $455.00 09/01/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209481
Principal investigator 1 ADC Therapeutics America, Inc. $3,240.68 08/25/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-901-101 No dispute reported 06/30/2026 1051209449
Principal investigator 1 ADC Therapeutics America, Inc. $3,353.18 08/25/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-901-101 No dispute reported 06/30/2026 1051209451
Principal investigator 1 ADC Therapeutics America, Inc. $2,500.00 08/25/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-901-101 No dispute reported 06/30/2026 1051209463
Principal investigator 1 ADC Therapeutics America, Inc. $3,353.18 08/25/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-901-101 No dispute reported 06/30/2026 1051209469
Principal investigator 1 Exelixis Inc. $1,650.00 08/25/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041942199
Principal investigator 1 Exelixis Inc. $530.00 08/23/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041942205
Principal investigator 1 Exelixis Inc. $1,650.00 07/24/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041942221
Principal investigator 1 Exelixis Inc. $3,000.00 07/12/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041942191
Principal investigator 1 Exelixis Inc. $1,650.00 07/12/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041942229
Principal investigator 1 ADC Therapeutics America, Inc. $93.75 06/30/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209393
Principal investigator 1 ADC Therapeutics America, Inc. $96.00 06/30/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209395
Principal investigator 1 Exelixis Inc. $1,650.00 06/12/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041942553
Principal investigator 1 ADC Therapeutics America, Inc. $478.13 06/09/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209397
Principal investigator 1 ADC Therapeutics America, Inc. $2,008.13 06/09/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209399
Principal investigator 1 ADC Therapeutics America, Inc. $1,873.13 06/09/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209401
Principal investigator 1 ADC Therapeutics America, Inc. $2,300.63 06/09/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209405
Principal investigator 1 ADC Therapeutics America, Inc. $1,985.63 06/09/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209407
Principal investigator 1 ADC Therapeutics America, Inc. $3,307.50 06/09/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209409
Principal investigator 1 ADC Therapeutics America, Inc. $3,110.63 06/09/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
ADCT-601-102 No dispute reported 06/30/2026 1051209411
Principal investigator 1 Exelixis Inc. $3,000.00 05/10/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041942251
Principal investigator 1 Exelixis Inc. $1,450.00 05/10/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041942309
Principal investigator 1 Exelixis Inc. $1,650.00 05/10/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041942337
Principal investigator 1 Exelixis Inc. $8,250.00 05/10/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041942345
Principal investigator 1 Exelixis Inc. $265.00 04/12/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041942245
Principal investigator 1 Exelixis Inc. $1,650.00 04/12/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041942301
Principal investigator 1 Exelixis Inc. $6,282.50 03/24/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041942175
Principal investigator 1 Exelixis Inc. $9,900.00 03/24/2023 Non-covered Recipient Entity
Sarah Cannon Research Institute, LLC
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041942183